Yusuf Gunay, Necdet Guler, Murat Dayangac, Fatih Taskesen, Onur Yaprak, Ertan Emek, Murat Akyildiz, Gulum Altaca, Yildiray Yuzer, Yaman Tokat – 15 November 2013 – Living donor liver transplantation (LDLT) is an accepted option for end‐stage liver disease, particularly in countries in which there are organ shortages. However, little is known about LDLT for obese patients. We sought to determine the effects of obesity on pretransplant living donor selection for obese recipients and their outcomes.

Li Jiang, Anque Liao, Lunan Yan, Jiayin Yang – 15 November 2013

Jessica Howell, Paul Gow, Peter Angus, Kumar Visvanathan – 15 November 2013 – Toll‐like receptors (TLRs) are pathogen recognition receptors that orchestrate the innate immune response and the subsequent adaptive immune response. TLRs can be triggered by exogenous ligands expressed by invading pathogens or by the release of endogenous ligands, such as that occurring through cellular injury during the transplantation process.

Deok‐Bog Moon, Sung‐Gyu Lee, Jung‐Man Namkoong, Shin Hwang, Ki‐Hun Kim, Chul‐Soo Ahn, Tae‐Yong Ha, Gi‐Won Song, Dong‐Hwan Jung, Gil‐Chun Park, Yo‐Han Park, Hyung‐Woo Park, Bo‐Hyun Jung, Sung‐Hwa Kang – 15 November 2013

Jian Sun, Qing Xie, Deming Tan, Qin Ning, Junqi Niu, Xuefan Bai, Rong Fan, Shijun Chen, Jun Cheng, Yanyan Yu, Hao Wang, Min Xu, Guangfeng Shi, Mobin Wan, Xinyue Chen, Hong Tang, Jifang Sheng, Xiaoguang Dou, Junping Shi, Hong Ren, Maorong Wang, Hongfei Zhang, Zhiliang Gao, Chengwei Chen, Hong Ma, Jidong Jia, Jinlin Hou – 14 November 2013 – An optimization strategy based on the Roadmap concept is supposed to improve the clinical outcomes of patients with suboptimal antiviral response. The aim of this study was to prove the concept with a multicenter, open‐label, randomized, controlled study.

Yunching Chen, Yuhui Huang, Thomas Reiberger, Annique M. Duyverman, Peigen Huang, Rekha Samuel, Lotte Hiddingh, Sylvie Roberge, Christina Koppel, Gregory Y. Lauwers, Andrew X. Zhu, Rakesh K. Jain, Dan G. Duda – 14 November 2013 – Sorafenib—a broad kinase inhibitor—is a standard therapy for advanced hepatocellular carcinoma (HCC) and has been shown to exert antifibrotic effects in liver cirrhosis, a precursor of HCC. However, the effects of sorafenib on tumor desmoplasia—and its consequences on treatment resistance—remain unknown.

Fateh Bazerbachi, Elizabeth Aby, John R. Lake – 10 November 2013

Angélique Gougelet, Cyril Torre, Philippe Veber, Chiara Sartor, Laura Bachelot, Pierre‐Damien Denechaud, Cécile Godard, Marthe Moldes, Anne‐Françoise Burnol, Céline Dubuquoy, Benoit Terris, François Guillonneau, Tao Ye, Michael Schwarz, Albert Braeuning, Christine Perret, Sabine Colnot – 9 November 2013 – β‐catenin signaling can be both a physiological and oncogenic pathway in the liver. It controls compartmentalized gene expression, allowing the liver to ensure its essential metabolic function.

Nassim Kamar, Jacques Izopet – 9 November 2013

Hua Tian, Chao Ge, Hong Li, Fangyu Zhao, Helei Hou, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Ming Yao, Jinjun Li – 9 November 2013 – Ribonucleotide reductase (RR)M2B is an enzyme belonging to the ribonucleotide reductase enzyme family, which is essential for DNA synthesis and repair. RRM2B plays an important role in tumor progression and metastasis; however, little is known about the expression and underlying molecular mechanisms of RRM2B in hepatocellular carcinoma (HCC).